First-in-human results show no transcaval-related bleeding after TAVR with novel closure device

Toby Rogers (Washington,DC, USA) tells Cardiovascular News at that preliminary feasibility data from 12 patients reveals that use of a dedicated closure device for the aorta after transcaval TAVR has “eliminated” transcaval-related bleeding. Transcaval-related bleeding remains a lingering concern that stops widespread adoption of this approach, Rogers explains.

Rogers, Toby

Dr. Rogers in an interventional cardiologist and scientific lead for the MedStar Heart & Vascular Institute Structural Heart Disease program. He has a special interest in all aspects of minimally invasive treatment of structural heart disease, including Transcatheter Aortic Valve Replacement (TAVR), Transcaval access, Transcatheter Electrosurgery (LAMPOON and BASILICA techniques), para-valvular leak closure, percutaneous treatment of mitral valve regurgitation including Mitraclip and Transcatheter Mitral Valve Replacement (TMVR), LAA occluder, percutaneous pulmonary and tricuspid valve interventions, and cerebral protection devices for TAVR.

Add comment

Editor’s Cardiovascular Pick

    Subscribeto receive the very best in medical videos